Cost-Utility Analysis of Screening for Diabetic Retinopathy in China
Health Data Science · 2022-01 · 2022
DOI: 10.34133/2022/9832185 ↗Kurz gefasst
Fachartikel in der Zeitschrift Health Data Science, online erschienen am 12.03.2022. Verfasst von Yue Zhang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Tongren Eye Center, Beijing Key Laboratory of Ophthalmology and Visual Sciences, Beijing Tongren Hospital, Capital Medical University, Beijin…. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Beijing Nova Program, Renmin University of China, Major Innovation Platform of Public Health & Disease Control and Prevention.
Abstract (Originalsprache)
Background
Diabetic retinopathy (DR) has been primarily indicated to cause vision impairment and blindness, while no studies have focused on the cost-utility of telemedicine-based and community screening programs for DR in China, especially in rural and urban areas, respectively.
Methods
We developed a Markov model to calculate the cost-utility of screening programs for DR in DM patients in rural and urban settings from the societal perspective. The incremental cost-utility ratio (ICUR) was calculated for the assessment.
Results
In the rural setting, the community screening program obtained 1 QALY with a cost of $4179 (95% CI 3859 to 5343), and the telemedicine screening program had an ICUR of $2323 (95% CI 1023 to 3903) compared with no screening, both of which satisfied the criterion of a significantly cost-effective health intervention. Likewise, community screening programs in urban areas generated an ICUR of $3812 (95% CI 2906 to 4167) per QALY gained, with telemedicine screening at an ICUR of $2437 (95% CI 1242 to 3520) compared with no screening, and both were also cost-effective. By further comparison, compared to community screening programs, telemedicine screening yielded an ICUR of 1212 (95% CI 896 to 1590) per incremental QALY gained in rural setting and 1141 (95% CI 859 to 1403) in urban setting, which both meet the criterion for a significantly cost-effective health intervention.
Conclusions
Both telemedicine and community screening for DR in rural and urban settings were cost-effective in China, and telemedicine screening programs were more cost-effective.
Autor:innen und Institutionen
- Beijing Tongren Eye Center, Beijing Key Laboratory of Ophthalmology and Visual Sciences, Beijing Tongren Hospital, Capital Medical University, Beijing Institute of Ophthalmology, Beijing, China.
- College of Computer Science, Nankai University, Tianjin, China.
- School of Agricultural Economics and Rural Development, Renmin University of China, Beijing, China.
- National Institute of Health Data Science at Peking University, Beijing, China.
- Beijing Institute of Ophthalmology, Beijing Tongren Hospital, Capital Medical University, Beijing Ophthalmology & Visual Science Key Lab, Beijing, China.
- School of Information and Electronics, Beijing Institute of Technology, Beijing, China.
ORCID-Profile: Yue Zhang, Ziwei Yang, Ningli Wang, Hanruo Liu
Förderung
- Beijing Nova Program
- Renmin University of China
- Major Innovation Platform of Public Health & Disease Control and Prevention
Zitieren
APA
Zhang, Y., Bai, W., Li, R., Du, Y., Sun, R., Li, T., Kang, H., Yang, Z., Tang, J., Wang, N., & Liu, H. (2022). Cost-Utility Analysis of Screening for Diabetic Retinopathy in China. Health Data Science, 2022. https://doi.org/10.34133/2022/9832185
Vancouver
Zhang Y, Bai W, Li R, Du Y, Sun R, Li T, et al. Cost-Utility Analysis of Screening for Diabetic Retinopathy in China. Health Data Science. 2022;2022. doi:10.34133/2022/9832185
BibTeX
@article{Zhang2022,
author = {Zhang, Yue and Bai, Weiling and Li, Ruyue and Du, Yifan and Sun, Runzhou and Li, Tao and Kang, Hong and Yang, Ziwei and Tang, Jianjun and Wang, Ningli and Liu, Hanruo},
title = {Cost-Utility Analysis of Screening for Diabetic Retinopathy in China},
journal = {Health Data Science},
year = {2022},
volume = {2022},
doi = {10.34133/2022/9832185}
}
EUVIMED